Could donor immune cells help tame tough leukemia?

NCT ID NCT05834244

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 33 times

Summary

This early-phase trial is testing whether adding natural killer (NK) cells from a healthy donor to the drugs azacitidine and venetoclax can help control acute myeloid leukemia (AML) in adults whose cancer has returned or not responded to treatment. About 32 participants will receive the combination and be monitored for side effects. The goal is to find a safer, more effective way to manage this aggressive blood cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Case Western Reserve University

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Email: •••••@•••••

    Contact

  • M.D. Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.